| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 0 | 0 | 10 | 30 | 1,240 |
| Sales Growth | unch | -100.00% | -66.67% | -97.58% | +40.91% |
| Net Income | -7,170 | -12,340 | -4,180 | 1,730 | -3,310 |
| Net Income Growth | +41.90% | -195.22% | -341.62% | +152.27% | +48.92% |
AIkido Pharma Inc (AIKI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York.